Labopharm to present at UBS Global Life Sciences Conference

Sep 24, 2004, 01:00 ET from Labopharm Inc.

    LAVAL, QC, Sept. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS)
 today announced that James R. Howard-Tripp, President and Chief Executive
 Officer of the Company, will present at the UBS Global Life Sciences
 Conference taking place September 27-30 at the Grand Hyatt Hotel in New York
 City. The Labopharm presentation is scheduled for 4:30 p.m. on Wednesday,
 September 29, 2004 in Ballroom D. A live webcast will be available at and and will be archived until October 30,
 2004. Please connect at least 15 minutes prior to the live webcast to ensure
 time to download required software.
     The UBS Global Life Sciences Conference will focus on the biotechnology,
 life sciences, media technology, and pharmaceutical fields. Over 300 companies
 from the United States, Europe and Asia-Pacific will present to an expected
 audience of over 3,000 attendees.
     About Labopharm Inc.
     Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical
 company focused on the development of drugs incorporating the Company's
 proprietary advanced controlled-release technology, Contramid(R). Contramid(R)
 can be applied to a wide variety of drugs in solid oral dosage form, improving
 their oral administration and performance and is used to develop products that
 are either bio-equivalent to existing, branded products, or are new branded
 products. The Company's pipeline includes a combination of both in-house and
 partnered programs with products both in clinical trials and in preclinical
 development. Labopharm is also developing implantable mini-tablets based on
 Contramid(R) for local administration of drugs and novel polymeric nano-
 delivery systems for delivery of water-insoluble and poorly bio-available
 drugs. For more information, please visit
     This press release contains forward-looking statements, which reflect the
 Corporation's current expectations regarding future events. The forward-
 looking statements involve risks and uncertainties. Actual events could differ
 materially from those projected herein and depend on a number of factors,
 including the successful and timely completion of clinical studies, the
 uncertainties related to the regulatory process and the commercialization of
 the drug thereafter. Investors should consult the Corporation's ongoing
 quarterly filings and annual reports for additional information on risks and
 uncertainties relating to these forward-looking statements. The reader is
 cautioned not to rely on these forward-looking statements. The Corporation
 disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.